Recovery & Repair · IGF-1 splice variant · Compounded 503A
PEG-MGF: pegylated mechano growth factor.
PEG-MGF is a pegylated form of mechano growth factor (MGF) — an alternative splice variant of IGF-1 produced locally in muscle in response to mechanical loading and damage. It activates satellite cells, the muscle stem-cell population responsible for repair and hypertrophy. The pegylation extends its very short native half-life into a clinically useful window.
Free shipping over $150 · Pay with card or crypto
What PEG-MGF is
MGF (mechano growth factor) is an alternative splice variant of insulin-like growth factor-1 (IGF-1Ec) produced by skeletal muscle in response to mechanical loading and damage. It is the local 'repair signal' that recruits muscle stem cells.
Native MGF has an extremely short half-life (minutes). PEG-MGF attaches a polyethylene glycol moiety to the molecule, extending half-life into hours-to-days and making clinical dosing feasible.
It is used in compounded practice as a recovery adjunct for adults with muscle-loss conditions, athletes (non-tested) working through structured rehabilitation, and longevity-focused patients addressing sarcopenia.
How it works
MGF binds a distinct receptor profile from systemic IGF-1, signaling preferentially to satellite cells (the muscle stem-cell population that sits adjacent to muscle fibers in a quiescent state).
Activation of satellite cells drives their proliferation, fusion with damaged muscle fibers, and incorporation of new myonuclei — the cellular basis of muscle repair and hypertrophy.
Mechanistically, MGF acts locally — in healthy biology it is produced by the damaged muscle itself and acts on adjacent stem cells. Exogenous PEG-MGF delivers this signal more broadly.
What patients use it for
Satellite-cell activation
The defining mechanism — recruits muscle stem cells, increasing the cellular substrate available for repair and growth.
Post-training recovery
May reduce time to recovery between heavy training sessions; particularly useful in concentrated training blocks or post-injury rehab.
Sarcopenia interest
Muscle-loss conditions (age-related sarcopenia, cachexia) involve impaired satellite-cell function — PEG-MGF is studied for this mechanism.
Complementary to GH-axis protocols
Works at a different level than systemic GH/IGF-1 — local muscle stem-cell signal rather than systemic anabolic drive.
Evidence summary
Yang SY, Goldspink G (FEBS Lett, 2002) — foundational paper characterizing MGF as a unique splice variant with distinct satellite-cell-activating activity.
Mills P et al. (Mol Ther, 2007) demonstrated MGF's role in muscle stem-cell activation and repair.
Philippou A, Barton ER (Trends Endocrinol Metab, 2014) reviewed MGF and other IGF-1 splice variants in muscle biology.
Direct large-scale human RCT data for PEG-MGF is limited; most evidence is preclinical and from related growth-factor literature.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Subcutaneous injection. Some protocols use local injection adjacent to a specific recovering muscle group (the 'site-specific' approach inherited from the local nature of native MGF signaling).
Often dosed post-training to amplify the satellite-cell response to the training stimulus.
Course-based use during heavy training blocks or rehabilitation periods is most common.
Safety and contraindications
Long-term human safety data is limited.
Theoretical concerns: any IGF-axis activator carries potential risk for tissues with growth-factor-sensitive pathology (active malignancy especially).
Contraindications: active cancer, pregnancy/lactation, pediatric use, known hypersensitivity.
Banned by WADA for competitive athletes (S2 growth factors / mimetics).
Not FDA-approved; compounded by licensed 503A pharmacies under physician prescription.
Who it's typically considered for
- Adults in structured rehabilitation from muscle injury or surgical recovery
- Athletes (non-tested) working through concentrated training blocks under physician supervision
- Patients with early sarcopenia pursuing muscle-protection protocols
- Patients combining with resistance training rather than substituting for it
Frequently asked questions
PEG-MGF vs IGF-1 LR3?
IGF-1 LR3 is a long-acting systemic IGF-1 analog — broad anabolic signal across all IGF-1R tissues. PEG-MGF is a splice variant targeting satellite cells specifically. Different signal, different application.
PEG-MGF vs BPC-157 or TB-500?
BPC-157 and TB-500 are general tissue-repair peptides (gut, tendon, ligament focus). PEG-MGF is muscle-stem-cell specific. They are complementary, not interchangeable.
Will PEG-MGF replace training?
No. Satellite-cell activation requires a stimulus to act on — without training, there is little muscle damage to repair and little hypertrophy signal to amplify.
Is PEG-MGF banned in sport?
Yes — WADA lists growth factors and growth-factor mimetics as prohibited (S2). Tested athletes should not use it.
Is PEG-MGF FDA-approved?
No. It is compounded by licensed 503A pharmacies under physician prescription for off-label use.
Can women use PEG-MGF?
Yes — particularly post-menopausal women addressing sarcopenia risk, under physician supervision. Muscle biology of satellite-cell activation is similar across sexes.
Sources
- Yang SY, Goldspink G. Different roles of the IGF-1Ec peptide (MGF) and mature IGF-1 in myoblast proliferation. FEBS Lett (2002). — pubmed.ncbi.nlm.nih.gov/12095641
- Philippou A, Barton ER. Optimizing IGF-I for skeletal muscle therapeutics. Growth Horm IGF Res (2014). — pubmed.ncbi.nlm.nih.gov/25117005
- Mills P et al. A synthetic mechano growth factor E peptide enhances myogenic precursor cell transplantation success. Mol Ther (2007). — pubmed.ncbi.nlm.nih.gov/17593928
Considering PEG-MGF?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.